<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04234724</url>
  </required_header>
  <id_info>
    <org_study_id>833684</org_study_id>
    <secondary_id>R01HL148769</secondary_id>
    <nct_id>NCT04234724</nct_id>
  </id_info>
  <brief_title>Physiological Effects of ANGPTL3 Variants in Humans</brief_title>
  <official_title>Physiological Effects of ANGPTL3 Variants in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the role of ANGPTL3, on lipid metabolism. To explore the role of this protein on
      glucose metabolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oral fast tolerance test, lipoprotein kinetics and a glucose tolerance test to evaluate the
      role of ANGPTL3, on lipid metabolism and to explore the role of this protein on glucose
      metabolism.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Suspended due to COVID-19
  </why_stopped>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The role of ANGPTL3 on lipid metabolism.</measure>
    <time_frame>through study completion, an average of 13 weeks</time_frame>
    <description>Assessing ApoB-containing lipoprotein fractional catabolic rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The role of this protein on glucose metabolism.</measure>
    <time_frame>through study completion, an average of 13 weeks</time_frame>
    <description>Looking for glucose area under the curve following Oral Glucose Tolerance Test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The role of ANPTL3 on fatty acids</measure>
    <time_frame>through study completion, an average of 13 weeks</time_frame>
    <description>Looking for fatty acids area under the curve following Oral Fat Tolerance Test</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hypocholesterolemia</condition>
  <arm_group>
    <arm_group_label>Variant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers with known ANGPTL3 variants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-variant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy volunteers with no ANGPTL3 variants</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Kinetics test, oral fat tolerance test, and an oral glucose tolerance test.</intervention_name>
    <description>Subjects will participate in a kinetics test, oral fat tolerance test, and an oral glucose tolerance test.</description>
    <arm_group_label>Non-variant</arm_group_label>
    <arm_group_label>Variant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects aged 18 or older meeting at least one of the following criteria

               1. Carrying genetic variants in the gene encoding for ANGPTL3,

               2. Unaffected controls matched for age, race, gender,

               3. Willing to follow study procedures

               4. Able to provide inform consent

                  Exclusion Criteria:

          -  Any medical or psychological conditions that, in the opinion of the investigator,
             would compromise the subject's safety or successful participation in the study, or
             confound the study data

          -  Taking any medication that, in the opinion of the investigator, would compromise the
             subject's safety or successful participation in the study, or confound the study data

          -  Women that are pregnant or nursing

          -  History of liver disease or abnormal liver function tests (&gt;2x upper limit of normal)

          -  History of kidney disease or chronic renal insufficiency (eGFR &lt;60 mL/min/1.73 m2)

          -  Uncontrolled hypertension (&gt;160/100 mmHg)

          -  Uncontrolled diabetes

          -  Anemia (hemoglobin &lt;11.0 mg/dL) History of a non-skin malignancy within the previous 5
             years Major surgery within the past 3 months

          -  History of any organ transplant

          -  History of alcohol or drug abuse

          -  Participation in clinical trials assessing the efficacy and safety of drugs affecting
             lipid metabolism within the past 6 weeks (or longer depending on the known half-life
             of the drug) that, in the opinion of the investigator, would compromise the subject's
             safety or successful participation in the study, or confound the study data

          -  Inability to comply to study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Cuchel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 21, 2020</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Angiopoietin-like protein 3 deficiency</keyword>
  <keyword>Lipid Metabolism</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT04234724/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

